27 October 2021
ADEPT study proves value of dental AI using AssistDent® AI software
Article taken from Dental Review News 26th October 2021: https://www.dentalreview.news/technology/24-dental-cad-cam-technology/7922-adept-study-proves-value-of-dental-ai … A spokesperson for the University of Manchester Dental School’s ADEPT (AssistDent Enamel-only...
25 October 2021
Rinicare confirms first European evaluation of its AI falls prevention technology
Manchester-based MedTech start-up Rinicare is working with Odense University Hospital in Denmark on a product evaluation of its unique falls reduction technology solution, SAFE. The Odense University Hospital team will evaluate the extent to which the SAFE platform (System to...
6 October 2021
Channel 4 Ventures invests in Maxwellia to support the launch of Lovima®
Maxwellia has announced a major investment from Channel 4 Ventures, striking an airtime-for-equity arrangement. The new investment will support the marketing campaign for Lovima®, helping fund a hugely impactful, innovative and educational 360° campaign designed to raise...
30 September 2021
Maxwellia announces appointment of Sara Al-Attbi as Medical Affairs Pharmacist
Maxwellia, the UK’s only company 100% dedicated to switching Rx to OTC medicines, has appointed Sara Al-Attbi to the newly created role of Medical Affairs Pharmacist. The role reflects Maxwellia’s focus on and commitment to widening access to medicines through...
22 September 2021
Infinity BiologiX, Cytox, and Vanguard Pharma announce the US launch of polygenic test to predict the risk of cognitive decline due to Alzheimer’s disease
21 September 2021: Piscataway, New Jersey; Oxford and Manchester, UK; Mahwah, New Jersey. Today, Infinity BiologiX, LLC (IBX), Cytox Ltd, and Vanguard Pharma announce the launch of the IBX Alzheimer’s Risk Test, powered by genoSCORETM. Physicians are able to pre-register...
21 September 2021
New study launched to investigate targeted treatments for Schizophrenia
Monument Therapeutics, in collaboration with the University of Nottingham, has announced a preclinical study to support the use of their non-invasive biomarker for cognitive impairment in schizophrenia. Currently, there are no treatments on the market for cognitive impairment...
20 September 2021
Boehringer Ingelheim and Oxford BioTherapeutics partnership advances second oncology drug candidate into the clinic
The Boehringer Ingelheim drug candidate was discovered in a partnership with Oxford BioTherapeutics and enabled by Oxford BioTherapeutics’ proprietary OGAP® target discovery platform … Oxford, UK; Morristown New Jersey and San Jose, Calif., 20th September 2021 - Oxford...
6 September 2021
Maxwellia strengthens its Marketing team with two new appointments
Maxwellia, the UK’s only company 100% dedicated to switching Rx to OTC medicines has created two new senior roles in its marketing team. The team expansion follows the success of the recent landmark reclassification of the progestogen only pill by the MHRA, a change...
1 September 2021
Rinicare’s continuous vital signs monitoring technology deployed across hospitals and Covid-19 health centres in India
Rinicare’s continuous vital signs monitoring technology platform, PRIME™, has started to be distributed across hospitals, health centres, and Covid-19 centres in Maharashtra state, India’s second most populous state with a population of 114 million people. The...
27 August 2021
£2m funding boost for Infex’s work on pandemic preparedness
Infex Therapeutics, the Alderley Park-based biotech developing new clinical pipeline of innovative drugs to treat critical priority infectious diseases, has completed an interim funding round worth £2.1m to expand its coronavirus therapeutics portfolio. Supported by...